

Review of: "[Review Article] A Comprehensive Overview on Pharmacological and Therapeutic Insights of Solanum nigrum Linn"

Haifa Chtourou¹

¹ University of Sfax

Potential competing interests: No potential competing interests to declare.

Comment for authors.

Overall, the review is well-written and informative. Addressing these minor points can further enhance clarity and engagement for the reader.

- **Abstract** : Use “anti-inflammatory” and not "antiinflammatory."
- **Introduction**
 - Make a reference after this sentence: “The species was first mentioned by renowned herbalists and naturalists Pliny the Elder and Pedanius Dioscorides in the first century AD.”
 - In the section 1.1. research methodology, line 5, make *S. nigrum* italic.
 - In the section 1.2. botanical description, line 2, make *S. nigrum* italic.
 - For fig.1, make a legend in each photo like photo 1 (a), photo 2 (b).... And describe this in the caption like (leaf (a), flower (b)....).
- **In part 2:** This sentence, line 3, needs assessment.

“The fruit is used as a diuretic, cathartic, hyper-aspiration, and asthma” will be, for example, “The fruit is employed for various medicinal purposes, acting as a diuretic, cathartic, and remedy for hyper-aspiration and asthma.”
- Chemical structures in part 2 are not mentioned in the text and need a figure caption.
- **In part 3**, all references are ancient. Please try to update references. All sections need improvement in structure and redaction, and it is recommended that authors should add the mechanism of action of some molecules isolated from extracts.
- All abbreviations need clarification.
- In the section 3.1 anti-diabetic activities, authors talk about the aqueous extract without specifying the plant part (leaf, flower, or other).
- In the section 3.1 anti-diabetic activities, authors use the abbreviation “aq.” It is recommended to use “aqueous extract.”

- The abbreviation "AESNB" is introduced without clarification. Please consider providing a brief explanation because it is first used.
- In section 3.2, all used references speak about the hepatoprotective efficiency, so it is irrelevant to repeat this in each paragraph.
- Section 3.2 needs improvement, and I suggest to add a paragraph speaking about the mechanism of action of the extract constituents to ameliorate the hepatoprotective activity.
- The abbreviation "GAPDH" is introduced without clarification.
- In section 3.8, SNL was introduced without clarification.
- In section 3.8, use 50 mg/ml instead of "fifty milligrammes per millilitre."
- **Part 4**, clinical trials talk about the therapeutic effect of *S. nigrum*. It is possible to merge this part with part 3.
-